Castle Biosciences Stock Today
| CSTL Stock | USD 20.44 0.10 0.49% |
PerformanceVery Weak
| Odds Of DistressLow
|
Castle Biosciences is selling for 20.44 as of the 20th of March 2025. This is a 0.49 percent decrease since the beginning of the trading day. The stock's lowest day price was 19.95. Castle Biosciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. The company was founded in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 28.51 M outstanding shares of which 1.93 M shares are currently shorted by private and institutional investors with about 4.57 trading days to cover. More on Castle Biosciences
Moving together with Castle Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Castle Stock Highlights
| CEO | Derek Maetzold |
| Business Concentration | Healthcare, Diagnostics & Research, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) |
Castle Biosciences (CSTL) is traded on NASDAQ Exchange in USA. It is located in 505 S. Friendswood Drive, Friendswood, TX, United States, 77546 and employs 761 people. Castle Biosciences is listed under Healthcare category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 584.25 M. Castle Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 28.51 M outstanding shares of which 1.93 M shares are currently shorted by private and institutional investors with about 4.57 trading days to cover.
Castle Biosciences currently holds about 273.17 M in cash with 64.87 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.39.
Check Castle Biosciences Probability Of Bankruptcy
Ownership AllocationCastle Biosciences holds a total of 28.51 Million outstanding shares. The majority of Castle Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Castle Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Castle Biosciences. Please pay attention to any change in the institutional holdings of Castle Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Castle Ownership Details
Castle Biosciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Castle Biosciences market risk premium is the additional return an investor will receive from holding Castle Biosciences long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.1) | |||
| Treynor Ratio | (0.95) |
Castle Stock Against Markets
Castle Biosciences Corporate Management
| Camilla Zuckero | Exec Communications | Profile | |
| John Abbott | VP Controller | Profile | |
| RN RN | Chief Officer | Profile | |
| Kristen RN | Chief Officer | Profile | |
| Tobin Juvenal | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.